DUNEDIN, New Zealand, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Bladder cancer diagnostics provider, Pacific Edge Diagnostics, has been notified by Novitas1 that the LCD: Biomarkers for Oncology (L35396) ...
Detailed price information for Pacific Edge Ltd Ord (PFGTF) from The Globe and Mail including charting and trades.
DUNEDIN, New Zealand, April 12, 2017 /PRNewswire/ -- Pacific Edge is proud to announce that its recent clinical study on Cxbladder Monitor's clinical performance and utility has been published in the ...
Pacific Edge (NZX:PEB), a cancer diagnostic company leading in the development and commercialisation of molecular diagnostic tests, has signed an agreement with FedMed, a national preferred provider ...
Pacific Edge Limited (NZX:PEB), a cancer diagnostics company developing and commercializing a suite of non-invasive tests for the detection and management of bladder cancer, announces today the ...
Pacific Edge Signs Agreement Extending Commercial Partnership with MidCentral District Health Board, to Encompass All Cxbladder Tests for Application Across the Clinical Pathway Cancer diagnostics ...
Dunedin-based Pacific Edge has released today the second product in its suite of diagnostic tests for the detection and management of bladder cancer. Cxbladder Triage complements the first molecular ...
Newly published research demonstrates that Cxbladder out performs other non-invasive bladder cancer diagnostics, announced Pacific Edge, Ltd. The new research comparing and ranking four widely used ...
Cancer diagnostic developer and service provider Pacific Edge is set to launch an e-commerce platform later this month to make its Cxbladder technology available to all New Zealanders from the ...
Pacific Edge, a cancer diagnostic company, has signed an agreement with FedMed, a provider network in the United States, to make Cxbladder available. The agreement provides FedMed's contracted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results